
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8849991/publications.pdf Version: 2024-02-01



ΔΝΝΑ ΜΛΙΟ

#	Article	IF	CITATIONS
1	Delayed Mortality Among Solid Organ Transplant Recipients Hospitalized for COVID-19. Clinical Infectious Diseases, 2024, 78, 711-718.	5.8	6
2	Neonatal Herpes Simplex Virus Infection: Epidemiology and Outcomes in the Modern Era. Journal of the Pediatric Infectious Diseases Society, 2022, 11, 94-101.	1.3	17
3	Booster Vaccination to Reduce SARS-CoV-2 Transmission and Infection. JAMA - Journal of the American Medical Association, 2022, 327, 327.	7.4	35
4	Trajectory of Viral RNA Load Among Persons With Incident SARS-CoV-2 G614 Infection (Wuhan Strain) in Association With COVID-19 Symptom Onset and Severity. JAMA Network Open, 2022, 5, e2142796.	5.9	57
5	Self-Assessed Severity as a Determinant of COVID-19 Symptom Specificity: A Longitudinal Cohort Study. Clinical Infectious Diseases, 2022, , .	5.8	0
6	Detection and kinetics of subgenomic SARS-CoV-2 RNA viral load in longitudinal diagnostic RNA positive samples. Journal of Infectious Diseases, 2022, , .	4.0	4
7	T cell response to intact SARS-CoV-2 includes coronavirus cross-reactive and variant-specific components. JCI Insight, 2022, 7, .	5.0	12
8	Comparison of Racial, Ethnic, and Geographic Location Diversity of Participants Enrolled in Clinic-Based vs 2 Remote COVID-19 Clinical Trials. JAMA Network Open, 2022, 5, e2148325.	5.9	24
9	Cervical Cancer Screening, Abnormal Results, and Follow-Up in Women with Substance Use-Related Diagnoses. Substance Abuse, 2022, 43, 925-931.	2.3	1
10	HSV-2-Specific Human Female Reproductive Tract Tissue Resident Memory T Cells Recognize Diverse HSV Antigens. Frontiers in Immunology, 2022, 13, 867962.	4.8	5
11	Antimicrobial resistance including Extended Spectrum Beta Lactamases (ESBL) among E. coli isolated from kenyan children at hospital discharge. PLoS Neglected Tropical Diseases, 2022, 16, e0010283.	3.0	12
12	Awareness and Correlates of HIV Pre-Exposure Prophylaxis (PrEP) Among HIV-negative People Who Access Syringe Services in Seattle, Washington. Substance Use and Misuse, 2022, 57, 337-343.	1.4	3
13	T cell receptor sequencing identifies prior SARS-CoV-2 infection and correlates with neutralizing antibodies and disease severity. JCI Insight, 2022, 7, .	5.0	26
14	Comparison of herpes simplex virus 1 genomic diversity between adult sexual transmission partners with genital infection. PLoS Pathogens, 2022, 18, e1010437.	4.7	4
15	Does providing laboratory confirmed STI results impact uptake of HIV pre-exposure prophylaxis (PrEP) uptake among Kenyan adolescents girls and young women? A descriptive analysis. Sexually Transmitted Infections, 2021, 97, 467-468.	1.9	5
16	Protection at First Sexual Intercourse Among Adolescent Girls and Young Women in Kenya. Archives of Sexual Behavior, 2021, 50, 219-227.	1.9	10
17	Hydroxychloroquine as Postexposure Prophylaxis to Prevent Severe Acute Respiratory Syndrome Coronavirus 2 Infection. Annals of Internal Medicine, 2021, 174, 344-352.	3.9	73
18	Clinical, laboratory, and temporal predictors of neutralizing antibodies against SARS-CoV-2 among COVID-19 convalescent plasma donor candidates. Journal of Clinical Investigation, 2021, 131, .	8.2	72

#	Article	IF	CITATIONS
19	In silico detection of SARS-CoV-2 specific B-cell epitopes and validation in ELISA for serological diagnosis of COVID-19. Scientific Reports, 2021, 11, 4290.	3.3	22
20	Comorbid illnesses are associated with altered adaptive immune responses to SARS-CoV-2. JCI Insight, 2021, 6, .	5.0	39
21	Human Antibody Responses Following Vaccinia Immunization Using Protein Microarrays and Correlation With Cell-Mediated Immunity and Antibody-Dependent Cellular Cytotoxicity Responses. Journal of Infectious Diseases, 2021, 224, 1372-1382.	4.0	10
22	A Public Health COVID-19 Vaccination Strategy to Maximize the Health Gains for Every Single Vaccine Dose. Annals of Internal Medicine, 2021, 174, 552-553.	3.9	29
23	B cells, antibody-secreting cells, and virus-specific antibodies respond to herpes simplex virus 2 reactivation in skin. Journal of Clinical Investigation, 2021, 131, .	8.2	14
24	CD101 genetic variants modify regulatory and conventional TÂcell phenotypes and functions. Cell Reports Medicine, 2021, 2, 100322.	6.5	5
25	Distinct populations of antigen specific tissue resident CD8 T cells in human cervix mucosa. JCI Insight, 2021, 6, .	5.0	10
26	Examining the dynamics of Epstein-Barr virus shedding in the tonsils and the impact of HIV-1 coinfection on daily saliva viral loads. PLoS Computational Biology, 2021, 17, e1009072.	3.2	9
27	Antibody responses to prophylactic quadrivalent human papillomavirus vaccine at 48Âmonths among HIV-infected girls and boys ages 9–14 in Kenya, Africa. Vaccine, 2021, 39, 4751-4758.	3.8	6
28	Self-collection of capillary blood using Tasso-SST devices for Anti-SARS-CoV-2 IgG antibody testing. PLoS ONE, 2021, 16, e0255841.	2.5	36
29	Tissue-Resident-Memory CD8+ T Cells Bridge Innate Immune Responses in Neighboring Epithelial Cells to Control Human Genital Herpes. Frontiers in Immunology, 2021, 12, 735643.	4.8	15
30	Cross-reactive and mono-reactive SARS-CoV-2 CD4+ T cells in prepandemic and COVID-19 convalescent individuals. PLoS Pathogens, 2021, 17, e1010203.	4.7	24
31	Implementation of a fully remote randomized clinical trial with cardiac monitoring. Communications Medicine, 2021, 1, .	4.2	4
32	Chemoprophylaxis Vaccination: Phase I Study to Explore Stage-specific Immunity to Plasmodium falciparum in US Adults. Clinical Infectious Diseases, 2020, 71, 1481-1490.	5.8	9
33	Reported Î ² -Lactam and Other Antibiotic Allergies in Solid Organ and Hematopoietic Cell Transplant Recipients. Clinical Infectious Diseases, 2020, 71, 1587-1594.	5.8	22
34	Multigroup, Adaptively Randomized Trials Are Advantageous for Comparing Coronavirus Disease 2019 (COVID-19) Interventions. Annals of Internal Medicine, 2020, 173, 576-577.	3.9	3
35	Sexually Transmitted Infections Among Kenyan Adolescent Girls and Young Women With Limited Sexual Experience. Frontiers in Public Health, 2020, 8, 303.	2.7	24
36	Herpes Simplex Virus Mistyping due to HSV-1 × HSV-2 Interspecies Recombination in Viral Gene Encoding Glycoprotein B. Viruses, 2020, 12, 860.	3.3	5

#	Article	IF	CITATIONS
37	Humoral Response to HPV16 Proteins in Persons with Anal High-Grade Squamous Intraepithelial Lesion or Anal Cancer. Cancer Epidemiology Biomarkers and Prevention, 2020, 29, 2255-2260.	2.5	3
38	Efficacy of hydroxychloroquine for post-exposure prophylaxis to prevent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection among adults exposed to coronavirus disease (COVID-19): a structured summary of a study protocol for a randomised controlled trial. Trials, 2020, 21, 475.	1.6	26
39	An Early Test-and-Treat Strategy for Severe Acute Respiratory Syndrome Coronavirus 2. Open Forum Infectious Diseases, 2020, 7, ofaa232.	0.9	16
40	Mechanisms of Endogenous HIV-1 Reactivation by Endocervical Epithelial Cells. Journal of Virology, 2020, 94, .	3.4	9
41	Estimating the Risk of Human Herpesvirus 6 and Cytomegalovirus Transmission to Ugandan Infants from Viral Shedding in Saliva by Household Contacts. Viruses, 2020, 12, 171.	3.3	20
42	Subclinical tuberculosis among adults with HIV: clinical features and outcomes in a South African cohort. BMC Infectious Diseases, 2019, 19, 14.	2.9	22
43	Cytomegalovirus shedding from breastmilk and mucosal sites in healthy postpartum women: A pilot study. Journal of Medical Virology, 2019, 91, 894-898.	5.0	11
44	Correlates of HIV detection among breastfeeding postpartum Kenyan women eligible under Option B+. PLoS ONE, 2019, 14, e0216252.	2.5	3
45	Therapeutic HSV-2 vaccine decreases recurrent virus shedding and recurrent genital herpes disease. Vaccine, 2019, 37, 3443-3450.	3.8	22
46	Comparisons of Human Immunodeficiency Virus Type 1 Envelope Variants in Blood and Genital Fluids near the Time of Male-to-Female Transmission. Journal of Virology, 2019, 93, .	3.4	4
47	Large, Stable, Contemporary Interspecies Recombination Events in Circulating Human Herpes Simplex Viruses. Journal of Infectious Diseases, 2019, 221, 1271-1279.	4.0	21
48	Effect of Human Papillomavirus Vaccine to Interrupt Recurrence of Vulvar and Anal Neoplasia (VIVA). JAMA Network Open, 2019, 2, e190819.	5.9	23
49	How low can you go: What is the safe threshold for platelet transfusions in patients with hematologic malignancy in sub-Saharan Africa. PLoS ONE, 2019, 14, e0211648.	2.5	4
50	The Effect of Hormonal Contraception and Menstrual Cycle Timing on Genital Herpes Simplex Virus-2 Shedding and Lesions. Sexually Transmitted Diseases, 2019, 46, 58-62.	1.7	2
51	Time Trends in First-Episode Genital Herpes Simplex Virus Infections in an Urban Sexually Transmitted Disease Clinic. Sexually Transmitted Diseases, 2019, 46, 795-800.	1.7	14
52	Viral Genetics Modulate Orolabial Herpes Simplex Virus Type 1 Shedding in Humans. Journal of Infectious Diseases, 2019, 219, 1058-1066.	4.0	13
53	Genome-wide association study (GWAS) of human host factors influencing viral severity of herpes simplex virus type 2 (HSV-2). Genes and Immunity, 2019, 20, 112-120.	4.1	17
54	Beyond Blood Smears: Qualification of Plasmodium 18S rRNA as a Biomarker for Controlled Human Malaria Infections. American Journal of Tropical Medicine and Hygiene, 2019, 100, 1466-1476.	1.4	41

#	Article	IF	CITATIONS
55	Nonprimary Maternal Cytomegalovirus Infection After Viral Shedding in Infants. Pediatric Infectious Disease Journal, 2018, 37, 627-631.	2.0	28
56	Analysis of Memory B-Cell Responses Reveals Suboptimal Dosing Schedule of a Licensed Vaccine. Journal of Infectious Diseases, 2018, 217, 572-580.	4.0	9
57	Determinants of Outcomes of Adenoviral Keratoconjunctivitis. Ophthalmology, 2018, 125, 1344-1353.	5.2	47
58	Increase in HSV shedding at initiation of antiretroviral therapy and decrease in shedding over time on antiretroviral therapy in HIV and HSV-2 infected persons. Aids, 2018, 32, 2525-2531.	2.2	12
59	128. Sexually Transmitted Infections Among Adolescent Girls in Thika, Kenya. Open Forum Infectious Diseases, 2018, 5, S9-S9.	0.9	0
60	Quadrivalent HPV vaccine in HIV-1-infected early adolescent girls and boys in Kenya: Month 7 and 12 post vaccine immunogenicity and correlation with immune status. Vaccine, 2018, 36, 7025-7032.	3.8	16
61	Limited Marginal Utility of Deep Sequencing for HIV Drug Resistance Testing in the Age of Integrase Inhibitors. Journal of Clinical Microbiology, 2018, 56, .	3.9	18
62	A Fixed Spatial Structure of CD8+ T Cells in Tissue during Chronic HSV-2 Infection. Journal of Immunology, 2018, 201, 1522-1535.	0.8	19
63	Ultrasensitive Capture of Human Herpes Simplex Virus Genomes Directly from Clinical Samples Reveals Extraordinarily Limited Evolution in Cell Culture. MSphere, 2018, 3, .	2.9	49
64	Effects of Different Doses of GEN-003, a Therapeutic Vaccine for Genital Herpes Simplex Virus-2, on Viral Shedding and Lesions: Results of a Randomized Placebo-Controlled Trial. Journal of Infectious Diseases, 2018, 218, 1890-1899.	4.0	31
65	Herpes Simplex Virus Shedding Rate: Surrogate Outcome for Genital Herpes Recurrence Frequency and Lesion Rates, and Phase 2 Clinical Trials End Point for Evaluating Efficacy of Antivirals. Journal of Infectious Diseases, 2018, 218, 1691-1699.	4.0	22
66	Prospective cohort study showing persistent HSV-2 shedding in women with genital herpes 2 years after acquisition. Sexually Transmitted Infections, 2018, 94, 568-570.	1.9	7
67	Autism Link to Herpes Simplex Virus 2 Antibody in Pregnancy Likely To Be Spurious. MSphere, 2017, 2, .	2.9	1
68	Worldwide circulation of HSV-2 × HSV-1 recombinant strains. Scientific Reports, 2017, 7, 44084.	3.3	81
69	Therapeutic Vaccine for Genital Herpes Simplex Virus-2 Infection: Findings From a Randomized Trial. Journal of Infectious Diseases, 2017, 215, 856-864.	4.0	55
70	Transient Oral Human Cytomegalovirus Infections Indicate Inefficient Viral Spread from Very Few Initially Infected Cells. Journal of Virology, 2017, 91, .	3.4	47
71	Virus and host-specific differences in oral human herpesvirus shedding kinetics among Ugandan women and children. Scientific Reports, 2017, 7, 13105.	3.3	18
72	Performance of Commercial Enzyme-Linked Immunoassays for Diagnosis of Herpes Simplex Virus-1 and Herpes Simplex Virus-2 Infection in a Clinical Setting. Sexually Transmitted Diseases, 2017, 44, 763-767.	1.7	18

#	Article	IF	CITATIONS
73	Highly conserved intragenic HSV-2 sequences: Results from next-generation sequencing of HSV-2 UL and US regions from genital swabs collected from 3 continents. Virology, 2017, 510, 90-98.	2.4	17
74	Hermeneutics of Herpes: The American Sexually Transmitted Diseases Association Distinguished Career Award Lecture. Sexually Transmitted Diseases, 2017, 44, 2-6.	1.7	1
75	Valganciclovir for the Suppression of Epstein-Barr Virus Replication. Journal of Infectious Diseases, 2017, 216, 198-202.	4.0	34
76	Sustained Responses to Measles Revaccination at 24 Months in HIV-infected Children on Antiretroviral Therapy in Kenya. Pediatric Infectious Disease Journal, 2017, 36, 1148-1155.	2.0	9
77	Selective Expression of CCR10 and CXCR3 by Circulating Human Herpes Simplex Virus-Specific CD8 T Cells. Journal of Virology, 2017, 91, .	3.4	13
78	Keratinocytes produce IL-17c to protect peripheral nervous systems during human HSV-2 reactivation. Journal of Experimental Medicine, 2017, 214, 2315-2329.	8.5	49
79	Genital Herpes. , 2017, , 567-574.e2.		0
80	Invasive Obstetric Procedures and Cesarean Sections in Women With Known Herpes Simplex Virus Status During Pregnancy. Open Forum Infectious Diseases, 2017, 4, ofx248.	0.9	2
81	Analysis of a Phase 2b Study of GEN-003, a Genital Herpes Immunotherapy, Showed Significant Reductions in Viral Shedding and Lesion Rate Vs Placebo. Open Forum Infectious Diseases, 2017, 4, S59-S59.	0.9	0
82	Human Metapneumovirus and Other Respiratory Viral Infections during Pregnancy and Birth, Nepal. Emerging Infectious Diseases, 2017, 23, .	4.3	14
83	Prevalence, Magnitude, and Correlates of HIV-1 Genital Shedding in Women on Antiretroviral Therapy. Journal of Infectious Diseases, 2017, 216, 1534-1540.	4.0	18
84	Dual-strain genital herpes simplex virus type 2 (HSV-2) infection in the US, Peru, and 8 countries in sub-Saharan Africa: A nested cross-sectional viral genotyping study. PLoS Medicine, 2017, 14, e1002475.	8.4	22
85	Effect of Condom Use on Per-act HSV-2 Transmission Risk in HIV-1, HSV-2-discordant Couples. Clinical Infectious Diseases, 2016, 62, civ908.	5.8	21
86	Genital HSV Shedding among Kenyan Women Initiating Antiretroviral Therapy. PLoS ONE, 2016, 11, e0163541.	2.5	3
87	HLA Class I and II alleles, heterozygosity and HLA-KIR interactions are associated with rates of genital HSV shedding and lesions. Genes and Immunity, 2016, 17, 412-418.	4.1	6
88	Effect of Pritelivir Compared With Valacyclovir on Genital HSV-2 Shedding in Patients With Frequent Recurrences. JAMA - Journal of the American Medical Association, 2016, 316, 2495.	7.4	67
89	Herpes Simplex Virus Type 1 Shedding in Tears and Nasal and Oral Mucosa of Healthy Adults. Sexually Transmitted Diseases, 2016, 43, 756-760.	1.7	76
90	A Single Human Papillomavirus Vaccine Dose Improves B Cell Memory in Previously Infected Subjects. EBioMedicine, 2016, 10, 55-64.	6.1	53

#	Article	IF	CITATIONS
91	Dynamics of Persistent Oral Cytomegalovirus Shedding During Primary Infection in Ugandan Infants. Journal of Infectious Diseases, 2016, 214, 1735-1743.	4.0	24
92	Attitudes and Willingness to Assume Risk of Experimental Therapy to Eradicate Genital Herpes Simplex Virus Infection. Sexually Transmitted Diseases, 2016, 43, 566-571.	1.7	3
93	No Evidence of Pritelivir Resistance Among Herpes Simplex Virus Type 2 Isolates After 4 Weeks of Daily Therapy. Journal of Infectious Diseases, 2016, 214, 258-264.	4.0	20
94	Patterns of human herpesvirus-8 oral shedding among diverse cohorts of human herpesvirus-8 seropositive persons. Infectious Agents and Cancer, 2016, 11, 7.	2.6	12
95	Extensive CD4 and CD8 T Cell Cross-Reactivity between Alphaherpesviruses. Journal of Immunology, 2016, 196, 2205-2218.	0.8	55
96	Consistent viral DNA quantification after prolonged storage at ambient temperature. Journal of Virological Methods, 2016, 228, 91-94.	2.1	7
97	Acyclovir Prophylaxis Reduces the Incidence of Herpes Zoster Among HIV-Infected Individuals: Results of a Randomized Clinical Trial. Journal of Infectious Diseases, 2016, 213, 551-555.	4.0	17
98	Status of vaccine research and development of vaccines for herpes simplex virus. Vaccine, 2016, 34, 2948-2952.	3.8	126
99	Mathematical modeling of herpes simplex virus-2 suppression with pritelivir predicts trial outcomes. Science Translational Medicine, 2016, 8, 324ra15.	12.4	29
100	Prospective Characterization of the Risk Factors for Transmission and Symptoms of Primary Human Herpesvirus Infections Among Ugandan Infants. Journal of Infectious Diseases, 2016, 214, 36-44.	4.0	60
101	Transient Increase in Herpes Simplex Virus Type 2 (HSV-2)–Associated Genital Ulcers Following Initiation of Antiretroviral Therapy in HIV/HSV-2–Coinfected Individuals. Journal of Infectious Diseases, 2016, 213, 1573-1578.	4.0	10
102	Genital Herpes Simplex Virus Type 2 Shedding Among Adults With and Without HIV Infection in Uganda. Journal of Infectious Diseases, 2016, 213, 439-447.	4.0	13
103	Mathematical Modeling Predicts that Increased HSV-2 Shedding in HIV-1 Infected Persons Is Due to Poor Immunologic Control in Ganglia and Genital Mucosa. PLoS ONE, 2016, 11, e0155124.	2.5	22
104	Evaluating risk factors for Clostridium difficile infection in adult and pediatric hematopoietic cell transplant recipients. Antimicrobial Resistance and Infection Control, 2015, 4, 41.	4.1	32
105	High Rate of β-Globin DNA Detection Validates Self-Sampling in Herpes Simplex Virus Shedding Studies. Sexually Transmitted Diseases, 2015, 42, 705-709.	1.7	7
106	Toll-like receptor gene variants and bacterial vaginosis among HIV-1 infected and uninfected African women. Genes and Immunity, 2015, 16, 362-365.	4.1	18
107	Oral and Vaginal Tenofovir for Genital Herpes Simplex Virus Type 2 Shedding in Immunocompetent Women: A Double-Blind, Randomized, Cross-over Trial. Journal of Infectious Diseases, 2015, 212, 1949-1956.	4.0	13
108	Host Genetic and Viral Determinants of HIV-1 RNA Set Point among HIV-1 Seroconverters from Sub-Saharan Africa. Journal of Virology, 2015, 89, 2104-2111.	3.4	22

#	Article	IF	CITATIONS
109	Dynamics of the Cytotoxic T Cell Response to a Model of Acute Viral Infection. Journal of Virology, 2015, 89, 4517-4526.	3.4	146
110	Comparison of lyophilized versus liquid modified vaccinia Ankara (MVA) formulations and subcutaneous versus intradermal routes of administration in healthy vaccinia-naÃ ⁻ ve subjects. Vaccine, 2015, 33, 5225-5234.	3.8	92
111	Plasma Cytokine Levels and Risk of HIV Type 1 (HIV-1) Transmission and Acquisition: A Nested Case-Control Study Among HIV-1–Serodiscordant Couples. Journal of Infectious Diseases, 2015, 211, 1451-1460.	4.0	47
112	Zoster Vaccination Increases the Breadth of CD4 ⁺ T Cells Responsive to Varicella Zoster Virus. Journal of Infectious Diseases, 2015, 212, 1022-1031.	4.0	45
113	Research Recruitment of Adult Survivors of Neonatal Infections: Is There a Role for Parental Consent?. American Journal of Bioethics, 2015, 15, 58-59.	0.9	1
114	Patient-Specific Neutralizing Antibody Responses to Herpes Simplex Virus Are Attributed to Epitopes on gD, gB, or Both and Can Be Type Specific. Journal of Virology, 2015, 89, 9213-9231.	3.4	31
115	Prevalence, Incidence, and Clearance of Anogenital Warts in Kenyan Men Reporting High-Risk Sexual Behavior, Including Men Who Have Sex With Men. Open Forum Infectious Diseases, 2015, 2, ofv070.	0.9	13
116	Plasma and Cerebrospinal Fluid Herpes Simplex Virus Levels at Diagnosis and Outcome of Neonatal Infection. Journal of Pediatrics, 2015, 166, 827-833.	1.8	47
117	Persistence of mucosal T-cell responses to herpes simplex virus type 2 in the female genital tract. Mucosal Immunology, 2015, 8, 115-126.	6.0	28
118	Maternal Valacyclovir and Infant Cytomegalovirus Acquisition: A Randomized Controlled Trial among HIV-Infected Women. PLoS ONE, 2014, 9, e87855.	2.5	40
119	Frequent Genital HSV-2 Shedding among Women during Labor in Soweto, South Africa. Infectious Diseases in Obstetrics and Gynecology, 2014, 2014, 1-8.	1.5	17
120	1224Defining herpes simplex virus type 2 sequence heterogeneity using next generation sequencing. Open Forum Infectious Diseases, 2014, 1, S42-S43.	0.9	0
121	1154Host and Pathogen Genetics Modulate HSV-1 Severity. Open Forum Infectious Diseases, 2014, 1, S342-S342.	0.9	1
122	1333Therapeutic HSV-2 vaccine (GEN003) results in durable reduction in genital lesions at 1 year. Open Forum Infectious Diseases, 2014, 1, S55-S56.	0.9	5
123	Unreported Antiretroviral Use by HIV-1–Infected Participants Enrolling in a Prospective Research Study. Journal of Acquired Immune Deficiency Syndromes (1999), 2014, 65, e90-e94.	2.1	32
124	Oral HHV-8 replication among women in Mombasa, Kenya. Journal of Medical Virology, 2014, 86, 1759-1765.	5.0	21
125	Herpes simplex virus-2 transmission probability estimates based on quantity of viral shedding. Journal of the Royal Society Interface, 2014, 11, 20140160.	3.4	67
126	Three Phase III Randomized Controlled Trials of Topical Resiquimod 0.01-Percent Gel To Reduce Anogenital Herpes Recurrences. Antimicrobial Agents and Chemotherapy, 2014, 58, 5016-5023.	3.2	6

#	Article	IF	CITATIONS
127	Seroprevalence of Herpes Simplex Virus Type 1 and 2 Among Pregnant Women, 1989-2010. JAMA - Journal of the American Medical Association, 2014, 312, 746.	7.4	26
128	Incidence of Herpes Simplex Virus Type 2 Infections in Africa: A Systematic Review. Open Forum Infectious Diseases, 2014, 1, ofu043.	0.9	24
129	Seroprevalence of Herpes Simplex Virus Type 1 and 2 Among Pregnant Women, 1989–2010. Obstetrical and Gynecological Survey, 2014, 69, 726-728.	0.4	0
130	Reduced human herpesvirus-8 oropharyngeal shedding associated with protease inhibitor-based antiretroviral therapy. Journal of Clinical Virology, 2014, 60, 127-132.	3.1	24
131	Current status and prospects for development of an HSV vaccine. Vaccine, 2014, 32, 1553-1560.	3.8	62
132	Helicase–Primase Inhibitor Pritelivir for HSV-2 Infection. New England Journal of Medicine, 2014, 370, 201-210.	27.0	128
133	Compartmentalized Cytomegalovirus Replication and Transmission in the Setting of Maternal HIV-1 Infection. Clinical Infectious Diseases, 2014, 58, 564-572.	5.8	44
134	Dissection of the Antibody Response against Herpes Simplex Virus Glycoproteins in Naturally Infected Humans. Journal of Virology, 2014, 88, 12612-12622.	3.4	63
135	Virologic and Immunologic Evidence of Multifocal Genital Herpes Simplex Virus 2 Infection. Journal of Virology, 2014, 88, 4921-4931.	3.4	55
136	Risk Factors for Anal Intraepithelial Neoplasia in Women With Genital Dysplasia. Obstetrics and Gynecology, 2014, 123, 183-184.	2.4	0
137	Impact of Body Mass Index on Immunogenicity of Pandemic H1N1 Vaccine in Children and Adults. Journal of Infectious Diseases, 2014, 210, 1270-1274.	4.0	43
138	Knowledge Is Power. JAMA Pediatrics, 2013, 167, 689.	6.2	8
139	Epidemiology, Clinical Presentation, and Antibody Response to Primary Infection With Herpes Simplex Virus Type 1 and Type 2 in Young Women. Clinical Infectious Diseases, 2013, 56, 344-351.	5.8	279
140	An artesunate-containing antimalarial treatment regimen did not suppress cytomegalovirus viremia. Journal of Clinical Virology, 2013, 58, 276-278.	3.1	18
141	Molecular epidemiology of respiratory syncytial virus transmission in childcare. Journal of Clinical Virology, 2013, 57, 343-350.	3.1	30
142	Immune surveillance by CD8αα+ skin-resident T cells in human herpes virus infection. Nature, 2013, 497, 494-497.	27.8	257
143	High-Dose Valacyclovir Decreases Plasma HIV-1 RNA More Than Standard-Dose Acyclovir in Persons Coinfected with HIV-1 and HSV-2. Journal of Acquired Immune Deficiency Syndromes (1999), 2013, 63, 201-208.	2.1	18
144	Daily Acyclovir to Decrease Herpes Simplex Virus Type 2 (HSV-2) Transmission from HSV-2/HIV-1 Coinfected Persons: A Randomized Controlled Trial. Journal of Infectious Diseases, 2013, 208, 1366-1374.	4.0	45

#	Article	IF	CITATIONS
145	Genital Herpes. , 2013, , 485-504.		0
146	Plasma Viral Loads During Early HIV-1 Infection Are Similar in Subtype C– and Non-Subtype C–Infected African Seroconverters. Journal of Infectious Diseases, 2013, 207, 1166-1170.	4.0	16
147	CD4 T-Cell Memory Responses to Viral Infections of Humans Show Pronounced Immunodominance Independent of Duration or Viral Persistence. Journal of Virology, 2013, 87, 2617-2627.	3.4	29
148	Rapid Viral Expansion and Short Drug Half-Life Explain the Incomplete Effectiveness of Current Herpes Simplex Virus 2-Directed Antiviral Agents. Antimicrobial Agents and Chemotherapy, 2013, 57, 5820-5829.	3.2	42
149	Partner Characteristics Predicting HIV-1 Set Point in Sexually Acquired HIV-1 Among African Seroconverters. AIDS Research and Human Retroviruses, 2013, 29, 164-171.	1.1	21
150	Short Communication: T Cell Activation in HIV-1/Herpes Simplex Virus-2-Coinfected Kenyan Women Receiving Valacyclovir. AIDS Research and Human Retroviruses, 2013, 29, 94-98.	1.1	7
151	Impact of human cytomegalovirus (CMV) infection on immune response to pandemic 2009 H1N1 influenza vaccine in healthy adults. Journal of Medical Virology, 2013, 85, 1557-1560.	5.0	54
152	Longitudinal study on oral shedding of herpes simplex virus 1 and varicellaâ€zoster virus in individuals infected with HIV. Journal of Medical Virology, 2013, 85, 1669-1677.	5.0	37
153	Rapid localized spread and immunologic containment define Herpes simplex virus-2 reactivation in the human genital tract. ELife, 2013, 2, e00288.	6.0	59
154	Mycobacterium tuberculosis Bacteremia in a Cohort of HIV-Infected Patients Hospitalized with Severe Sepsis in Uganda–High Frequency, Low Clinical Sand Derivation of a Clinical Prediction Score. PLoS ONE, 2013, 8, e70305.	2.5	62
155	Determinants of Per-Coital-Act HIV-1 Infectivity Among African HIV-1–Serodiscordant Couples. Journal of Infectious Diseases, 2012, 205, 358-365.	4.0	291
156	Valacyclovir Suppressive Therapy Reduces Plasma and Breast Milk HIV-1 RNA Levels During Pregnancy and Postpartum: A Randomized Trial. Journal of Infectious Diseases, 2012, 205, 366-375.	4.0	31
157	A Prospective Cohort Study of Partner Testing for Herpes Simplex Virus and Sexual Behavior During Pregnancy. Journal of Infectious Diseases, 2012, 206, 486-494.	4.0	11
158	Higher Antigen Content Improves the Immune Response to 2009 H1N1 Influenza Vaccine in HIV-Infected Adults: A Randomized Clinical Trial. Journal of Infectious Diseases, 2012, 205, 703-712.	4.0	26
159	ASP2151 for the Treatment of Genital Herpes: A Randomized, Double-Blind, Placebo- and Valacyclovir-Controlled, Dose-Finding Study. Journal of Infectious Diseases, 2012, 205, 1100-1110.	4.0	71
160	Peripheral Blood CD4 T-Cell and Plasmacytoid Dendritic Cell (pDC) Reactivity to Herpes Simplex Virus 2 and pDC Number Do Not Correlate with the Clinical or Virologic Severity of Recurrent Genital Herpes. Journal of Virology, 2012, 86, 9952-9963.	3.4	23
161	Acyclovir Achieves a Lower Concentration in African HIV-Seronegative, Herpes Simplex Virus 2-Seropositive Women than in Non-African Populations. Antimicrobial Agents and Chemotherapy, 2012, 56, 2777-2779.	3.2	19
162	Primary Maternal Herpes Simplex Virus-1 Gingivostomatitis During Pregnancy and Neonatal Herpes: Case Series and Literature Review. Journal of the Pediatric Infectious Diseases Society, 2012, 1, 299-305.	1.3	3

#	Article	IF	CITATIONS
163	Clinical and Virologic Response to Episodic Acyclovir for Genital Ulcers Among HIV-1 Seronegative, Herpes Simplex Virus Type 2 Seropositive African Women: A Randomized, Placebo-Controlled Trial. Sexually Transmitted Diseases, 2012, 39, 21-24.	1.7	6
164	Case-Crossover Analysis of Condom Use and Herpes Simplex Virus Type 2 Acquisition. Sexually Transmitted Diseases, 2012, 39, 388-393.	1.7	18
165	Clinical Burden of Herpes Simplex Virus Disease in People With Human Immunodeficiency Virus. Sexually Transmitted Diseases, 2012, 39, 372-376.	1.7	2
166	The impact of early monitored management on survival in hospitalized adult Ugandan patients with severe sepsis. Critical Care Medicine, 2012, 40, 2050-2058.	0.9	109
167	Standard-dose and high-dose daily antiviral therapy for short episodes of genital HSV-2 reactivation: three randomised, open-label, cross-over trials. Lancet, The, 2012, 379, 641-647.	13.7	104
168	Immunogenicity and Safety of Varying Dosages of a Monovalent 2009 H1N1 Influenza Vaccine Given With and Without AS03 Adjuvant System in Healthy Adults and Older Persons. Journal of Infectious Diseases, 2012, 206, 811-820.	4.0	36
169	Phase 2 assessment of the safety and immunogenicity of two inactivated pandemic monovalent H1N1 vaccines in adults as a component of the U.S. pandemic preparedness plan in 2009. Vaccine, 2012, 30, 4240-4248.	3.8	27
170	An Effector Phenotype of CD8 ⁺ T Cells at the Junction Epithelium during Clinical Quiescence of Herpes Simplex Virus 2 Infection. Journal of Virology, 2012, 86, 10587-10596.	3.4	55
171	Efficacy Results of a Trial of a Herpes Simplex Vaccine. New England Journal of Medicine, 2012, 366, 34-43.	27.0	439
172	Efficacy of a Viral Load-Based, Risk-Adapted, Preemptive Treatment Strategy for Prevention of Cytomegalovirus Disease after Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation, 2012, 18, 1687-1699.	2.0	145
173	Mortality in members of HIV-1 serodiscordant couples in Africa and implications for antiretroviral therapy initiation: Results of analyses from a multicenter randomized trial. BMC Infectious Diseases, 2012, 12, 277.	2.9	6
174	Infant Safety during and after Maternal Valacyclovir Therapy in Conjunction with Antiretroviral HIV-1 Prophylaxis in a Randomized Clinical Trial. PLoS ONE, 2012, 7, e34635.	2.5	13
175	Multiple versus single virus respiratory infections: viral load and clinical disease severity in hospitalized children. Influenza and Other Respiratory Viruses, 2012, 6, 71-77.	3.4	175
176	Identifying predictors of increased quantities of human Herpesvirus 8 DNA detection at oropharyngeal and plasma sites among Ugandan adults with and without HIV and Kaposi Sarcoma. Infectious Agents and Cancer, 2012, 7, .	2.6	1
177	Cross-presentation and genome-wide screening reveal candidate T cells antigens for a herpes simplex virus type 1 vaccine. Journal of Clinical Investigation, 2012, 122, 654-673.	8.2	83
178	Cross-presentation and genome-wide screening reveal candidate T cells antigens for a herpes simplex virus type 1 vaccine. Journal of Clinical Investigation, 2012, 122, 3024-3024.	8.2	1
179	Effects of Valacyclovir on Markers of Disease Progression in Postpartum Women Co-Infected with HIV-1 and Herpes Simplex Virus-2. PLoS ONE, 2012, 7, e38622.	2.5	7
180	Using Plasma Viral Load to Guide Antiretroviral Therapy Initiation to Prevent HIV-1 Transmission. PLoS ONE, 2012, 7, e51192.	2.5	8

#	Article	IF	CITATIONS
181	Herpes Simplex Virus Genital Infection. , 2012, , 311-318.		0
182	The effects of daily distress and personality on genital HSV shedding and lesions in a randomized, double-blind, placebo-controlled, crossover trial of acyclovir in HSV-2 seropositive women. Brain, Behavior, and Immunity, 2011, 25, 1475-1481.	4.1	21
183	Development of an interferon-gamma ELISPOT assay to detect human T cell responses to HSV-2. Vaccine, 2011, 29, 7058-7066.	3.8	12
184	Safety and immunogenicity of long HSV-2 peptides complexed with rhHsc70 in HSV-2 seropositive persons. Vaccine, 2011, 29, 8520-8529.	3.8	70
185	Viral Linkage in HIV-1 Seroconverters and Their Partners in an HIV-1 Prevention Clinical Trial. PLoS ONE, 2011, 6, e16986.	2.5	80
186	O3-S5.02 Frequent breakthrough genital HSV-2 shedding on standard and high dose valacyclovir. Sexually Transmitted Infections, 2011, 87, A79-A79.	1.9	2
187	Predictors of Survival After a Diagnosis of Non-Hodgkin Lymphoma in a Resource-Limited Setting: A Retrospective Study on the Impact of HIV Infection and Its Treatment. Journal of Acquired Immune Deficiency Syndromes (1999), 2011, 56, 312-319.	2.1	39
188	Increased risk of HIV-1 transmission in pregnancy. Aids, 2011, 25, 1887-1895.	2.2	219
189	Herpes zoster incidence in a multicenter cohort of solid organ transplant recipients. Transplant Infectious Disease, 2011, 13, 15-23.	1.7	83
190	A Post-Trial Assessment of Factors Influencing Study Drug Adherence in a Randomized Biomedical HIV-1 Prevention Trial. AIDS and Behavior, 2011, 15, 897-904.	2.7	10
191	Treatment with valacyclovir, famciclovir, or antiretrovirals reduces human herpesvirusâ€8 replication in HIVâ€1 seropositive men. Journal of Medical Virology, 2011, 83, 1696-1703.	5.0	22
192	Safety and Immunogenicity of Influenza A H5 Subunit Vaccines: Effect of Vaccine Schedule and Antigenic Variant. Journal of Infectious Diseases, 2011, 203, 666-673.	4.0	56
193	Detailed analysis of mucosal herpes simplex virus-2 replication kinetics with and without antiviral therapy. Journal of Antimicrobial Chemotherapy, 2011, 66, 2593-2600.	3.0	30
194	Genital HSV Detection among HIV-1-Infected Pregnant Women in Labor. Infectious Diseases in Obstetrics and Gynecology, 2011, 2011, 1-4.	1.5	18
195	Genital Shedding of Herpes Simplex Virus Among Symptomatic and Asymptomatic Persons With HSV-2 Infection. JAMA - Journal of the American Medical Association, 2011, 305, 1441.	7.4	237
196	Clinician and Patient Recognition of Anogenital Herpes Disease in HIV Positive Men Who Have Sex With Men. Sexually Transmitted Diseases, 2011, 38, 833-836.	1.7	3
197	Genital HIV-1 RNA Predicts Risk of Heterosexual HIV-1 Transmission. Science Translational Medicine, 2011, 3, 77ra29.	12.4	265
198	Herpes simplex virus type 2 serological testing and psychosocial harm: a systematic review. Sexually Transmitted Infections, 2011, 87, 594-600.	1.9	25

#	Article	IF	CITATIONS
199	Clinical Experience in Adults and Children Treated with Intravenous Peramivir for 2009 Influenza A (H1N1) Under an Emergency IND Program in the United States. Clinical Infectious Diseases, 2011, 52, 695-706.	5.8	94
200	Herpes Simplex Virus Type 2 Suppressive Therapy with Acyclovir or Valacyclovir Does Not Select for Specific HIV-1 Resistance in HIV-1/HSV-2 Dually Infected Persons. Journal of Infectious Diseases, 2011, 203, 117-121.	4.0	18
201	The Kinetics of Mucosal Herpes Simplex Virus–2 Infection in Humans: Evidence for Rapid Viral-Host Interactions. Journal of Infectious Diseases, 2011, 204, 554-561.	4.0	54
202	Persistent Genital Herpes Simplex Virus-2 Shedding Years Following the First Clinical Episode. Journal of Infectious Diseases, 2011, 203, 180-187.	4.0	67
203	HSV-2: in pursuit of a vaccine. Journal of Clinical Investigation, 2011, 121, 4600-4609.	8.2	118
204	Cytomegalovirus Viremia as a Risk Factor for Mortality Prior to Antiretroviral Therapy among HIV-Infected Gold Miners in South Africa. PLoS ONE, 2011, 6, e25571.	2.5	40
205	Genomewide Association Study for Determinants of HIV-1 Acquisition and Viral Set Point in HIV-1 Serodiscordant Couples with Quantified Virus Exposure. PLoS ONE, 2011, 6, e28632.	2.5	80
206	Influenza-Associated Cystic Fibrosis Pulmonary Exacerbations. Chest, 2010, 137, 852-860.	0.8	75
207	Rapidly Cleared Episodes of Oral and Anogenital Herpes Simplex Virus Shedding in HIV-Infected Adults. Journal of Acquired Immune Deficiency Syndromes (1999), 2010, 54, 482-488.	2.1	38
208	Diversity in CD8+ T Cell Function and Epitope Breadth Among Persons with Genital Herpes. Journal of Clinical Immunology, 2010, 30, 703-722.	3.8	54
209	Utility of the Beck Depression Inventory to screen for and track depression in injection drug users seeking hepatitis C treatment. General Hospital Psychiatry, 2010, 32, 426-432.	2.4	17
210	Clinical presentation and outcome of epidemic Kaposi sarcoma in Ugandan children. Pediatric Blood and Cancer, 2010, 54, 670-674.	1.5	63
211	Pregnancy, Contraceptive Use, and HIV Acquisition in HPTN 039: Relevance for HIV Prevention Trials Among African Women. Journal of Acquired Immune Deficiency Syndromes (1999), 2010, 53, 606-613.	2.1	81
212	Estimating the Impact of Plasma HIV-1 RNA Reductions on Heterosexual HIV-1 Transmission Risk. PLoS ONE, 2010, 5, e12598.	2.5	129
213	Respiratory Failure Caused by 2009 Novel Influenza A/H1N1 in a Hematopoietic Stem-Cell Transplant Recipient: Detection of Extrapulmonary H1N1 RNA and Use of Intravenous Peramivir. Annals of Internal Medicine, 2010, 152, 619.	3.9	24
214	Detailed Characterization of T Cell Responses to Herpes Simplex Virus-2 in Immune Seronegative Persons. Journal of Immunology, 2010, 184, 3250-3259.	0.8	56
215	Effect of Acyclovir on HIVâ€1 Set Point among Herpes Simplex Virus Type 2–Seropositive Persons during Early HIVâ€1 Infection. Journal of Infectious Diseases, 2010, 202, 734-738.	4.0	11
216	Use of Acyclovir for Suppression of Human Immunodeficiency Virus Infection Is Not Associated with Genotypic Evidence of Herpes Simplex Virus Type 2 Resistance to Acyclovir: Analysis of Specimens from Three Phase III Trials. Journal of Clinical Microbiology, 2010, 48, 3496-3503.	3.9	17

#	Article	IF	CITATIONS
217	Acyclovir and Transmission of HIV-1 from Persons Infected with HIV-1 and HSV-2. New England Journal of Medicine, 2010, 362, 427-439.	27.0	476
218	Frequent and Prolonged Shedding of Bocavirus in Young Children Attending Daycare. Journal of Infectious Diseases, 2010, 201, 1625-1632.	4.0	192
219	Respiratory Virus Pneumonia after Hematopoietic Cell Transplantation (HCT): Associations between Viral Load in Bronchoalveolar Lavage Samples, Viral RNA Detection in Serum Samples, and Clinical Outcomes of HCT. Journal of Infectious Diseases, 2010, 201, 1404-1413.	4.0	82
220	Overlapping Reactivations of Herpes Simplex Virus Type 2 in the Genital and Perianal Mucosa. Journal of Infectious Diseases, 2010, 201, 499-504.	4.0	29
221	Mucosal host immune response predicts the severity and duration of herpes simplex virus-2 genital tract shedding episodes. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 18973-18978.	7.1	112
222	Clinical and Virologic Efficacy of Herpes Simplex Virus Type 2 Suppression by Acyclovir in a Multicontinent Clinical Trial. Journal of Infectious Diseases, 2010, 201, 1164-1168.	4.0	27
223	APOE genotype is associated with oral herpetic lesions but not genital or oral herpes simplex virus shedding. Sexually Transmitted Infections, 2010, 86, 202-206.	1.9	40
224	Rapid Polymerase Chain Reaction Assay to Detect Herpes Simplex Virus in the Genital Tract of Women in Labor. Obstetrics and Gynecology, 2010, 115, 1209-1216.	2.4	28
225	Daily aciclovir for HIV-1 disease progression in people dually infected with HIV-1 and herpes simplex virus type 2: a randomised placebo-controlled trial. Lancet, The, 2010, 375, 824-833.	13.7	142
226	Population Level Impact of an Imperfect Prophylactic Vaccine for Herpes Simplex Virus-2. Sexually Transmitted Diseases, 2010, 37, 290-297.	1.7	36
227	Gender Differences in Clinical Presentation and Outcomes of Epidemic Kaposi Sarcoma in Uganda. PLoS ONE, 2010, 5, e13936.	2.5	44
228	Characteristics of HIV-1 Discordant Couples Enrolled in a Trial of HSV-2 Suppression to Reduce HIV-1 Transmission: The Partners Study. PLoS ONE, 2009, 4, e5272.	2.5	71
229	Hepatitis C Virus Is Infrequently Evaluated and Treated in an Urban HIV Clinic Population. AIDS Patient Care and STDs, 2009, 23, 925-929.	2.5	26
230	Evasion of the Mucosal Innate Immune System by Herpes Simplex Virus Type 2. Journal of Virology, 2009, 83, 12559-12568.	3.4	54
231	Clinical Correlates of Herpes Simplex Virus Viremia among Hospitalized Adults. Clinical Infectious Diseases, 2009, 49, 1295-1301.	5.8	71
232	The Acceptance of HSV-Testing Partners of HSV-2 Seronegative Pregnant Women. Sexually Transmitted Diseases, 2009, 36, 211-215.	1.7	6
233	Use of the designation "shedder" in mucosal detection of herpes simplex virus DNA involving repeated sampling. Sexually Transmitted Infections, 2009, 85, 270-275.	1.9	22
234	Detection of Bocavirus in Saliva of Children with and without Respiratory Illness. Journal of Clinical Microbiology, 2009, 47, 4131-4132.	3.9	45

#	Article	IF	CITATIONS
235	Frequent Release of Low Amounts of Herpes Simplex Virus from Neurons: Results of a Mathematical Model. Science Translational Medicine, 2009, 1, 7ra16.	12.4	100
236	Herpes Simplex Virus Infections in Solid Organ Transplant Recipients. American Journal of Transplantation, 2009, 9, S104-S107.	4.7	33
237	Persistence of HIV-1 receptor–positive cells after HSV-2 reactivation is a potential mechanism for increased HIV-1 acquisition. Nature Medicine, 2009, 15, 886-892.	30.7	341
238	Maternal and Neonatal Herpes Simplex Virus Infections. New England Journal of Medicine, 2009, 361, 1376-1385.	27.0	517
239	HSV suppression reduces seminal HIV-1 levels in HIV-1/HSV-2 co-infected men who have sex with men. Aids, 2009, 23, 479-483.	2.2	45
240	A Pooled Analysis of the Effect of Condoms in Preventing HSV-2 Acquisition. Archives of Internal Medicine, 2009, 169, 1233.	3.8	115
241	Inadequacy of Plasma Acyclovir Levels at Delivery in Patients With Genital Herpes Receiving Oral Acyclovir Suppressive Therapy in Late Pregnancy. Journal of Obstetrics and Gynaecology Canada, 2009, 31, 1137-1143.	0.7	5
242	Impact of HIV Infection and Kaposi Sarcoma on Human Herpesvirus-8 Mucosal Replication and Dissemination in Uganda. PLoS ONE, 2009, 4, e4222.	2.5	50
243	Oral mucosal reactivation rates of herpesviruses among HIVâ€I seropositive persons. Journal of Medical Virology, 2008, 80, 1153-1159.	5.0	36
244	Effect of aciclovir on HIV-1 acquisition in herpes simplex virus 2 seropositive women and men who have sex with men: a randomised, double-blind, placebo-controlled trial. Lancet, The, 2008, 371, 2109-2119.	13.7	412
245	Phase I Dose-Escalation Study of a Monovalent Heat Shock Protein 70-Herpes Simplex Virus Type 2 (HSV-2) Peptide-Based Vaccine Designed To Prime or Boost CD8 T-Cell Responses in HSV-Nail`ve and HSV-2-Infected Subjects. Vaccine Journal, 2008, 15, 773-782.	3.1	23
246	Phase I Study of a Herpes Simplex Virus Type 2 (HSV-2) DNA Vaccine Administered to Healthy, HSV-2-Seronegative Adults by a Needle-Free Injection System. Vaccine Journal, 2008, 15, 1638-1643.	3.1	65
247	Safety and Immunogenicity of a Bivalent Cytomegalovirus DNA Vaccine in Healthy Adult Subjects. Journal of Infectious Diseases, 2008, 197, 1634-1642.	4.0	136
248	One-Day Regimen of Valacyclovir for Treatment of Recurrent Genital Herpes Simplex Virus 2 Infection. Sexually Transmitted Diseases, 2008, 35, 383-386.	1.7	14
249	Prevalence and Correlates of Human Herpesvirus 8 Infection Among Peruvian Men Who Have Sex With Men. Journal of Acquired Immune Deficiency Syndromes (1999), 2008, 49, 557-562.	2.1	14
250	Herpes Simplex Virus Viremia during Primary Genital Infection. Journal of Infectious Diseases, 2008, 198, 31-34.	4.0	70
251	Herpes Simplex Virus (HSV)–Suppressive Therapy Decreases Plasma and Genital HIVâ€1 Levels in HSVâ€2/HIVâ Coinfected Women: A Randomized, Placeboâ€Controlled, Crossâ€Over Trial. Journal of Infectious Diseases, 2008, 198, 1804-1808.	€ 1 4.0	129
252	Rapidly Cleared Episodes of Herpes Simplex Virus Reactivation in Immunocompetent Adults. Journal of Infectious Diseases, 2008, 198, 1141-1149.	4.0	233

#	Article	IF	CITATIONS
253	Valganciclovir for Suppression of Human Herpesvirus–8 Replication: A Randomized, Doubleâ€Blind, Placebo ontrolled, Crossover Trial. Journal of Infectious Diseases, 2008, 198, 23-30.	4.0	147
254	Acceptance of a Rapid Herpes Test in Labour: Survey of Attitudes of Patients and Health Care Providers. Journal of Obstetrics and Gynaecology Canada, 2008, 30, 776-780.	0.7	4
255	Does Frequency of Genital Herpes Recurrences Predict Risk of Transmission? Further Analysis of the Valacyclovir Transmission Study. Sexually Transmitted Diseases, 2008, 35, 124-128.	1.7	13
256	Persistent Kaposi sarcoma in the era of highly active antiretroviral therapy: characterizing the predictors of clinical response. Aids, 2008, 22, 937-945.	2.2	103
257	Internet and Email Use Among STD Clinic Patients. Sexually Transmitted Diseases, 2008, 35, 960-965.	1.7	11
258	From the NIH: Proceedings of a Workshop on the Importance of Self-Obtained Vaginal Specimens for Detection of Sexually Transmitted Infections. Sexually Transmitted Diseases, 2008, 35, 8-13.	1.7	90
259	Healthcare Seeking and Sexual Behavior Among Patients with Symptomatic Newly Acquired Genital Herpes. Sexually Transmitted Diseases, 2008, 35, 1015-1021.	1.7	10
260	Genital Herpes Has Played a More Important Role than Any Other Sexually Transmitted Infection in Driving HIV Prevalence in Africa. PLoS ONE, 2008, 3, e2230.	2.5	219
261	Herpes Simplex Virus (HSV) Suppression with Valacyclovir Reduces Rectal and Blood Plasma HIVâ€1 Levels in HIVâ€1/HSVâ€2–Seropositive Men: A Randomized, Doubleâ€Blind, Placebo ontrolled Crossover Trial. Journal of Infectious Diseases, 2007, 196, 1500-1508.	4.0	176
262	Incident and prevalent herpes simplex virus type 2 infection increases risk of HIV acquisition among women in Uganda and Zimbabwe. Aids, 2007, 21, 1515-1523.	2.2	91
263	HSV-2 Serologic Testing in an HMO Population: Uptake and Psychosocial Sequelae. Sexually Transmitted Diseases, 2007, 34, 718-725.	1.7	15
264	Famciclovir Reduces Viral Mucosal Shedding in HSV-Seropositive Persons. Sexually Transmitted Diseases, 2007, 34, 900-907.	1.7	32
265	HIV prevalence, previous HIV testing, and condom use with clients and regular partners among Senegalese commercial sex workers. Sexually Transmitted Infections, 2007, 83, 534-540.	1.9	100
266	Longitudinal study of herpes simplex virus type 2 infection using viral dynamic modelling. Sexually Transmitted Infections, 2007, 83, 359-364.	1.9	37
267	Virus-specific CD8+ T cells accumulate near sensory nerve endings in genital skin during subclinical HSV-2 reactivation. Journal of Experimental Medicine, 2007, 204, 595-603.	8.5	315
268	Optimizing PCR Positivity Criterion for Detection of Herpes Simplex Virus DNA on Skin and Mucosa. Journal of Clinical Microbiology, 2007, 45, 1618-1620.	3.9	80
269	Frequent and Asymptomatic Oropharyngeal Shedding of Human Herpesvirus 8 among Immunocompetent Men. Journal of Infectious Diseases, 2007, 195, 30-36.	4.0	97
270	Polymorphisms in <i>TLR2</i> Are Associated with Increased Viral Shedding and Lesional Rate in Patients with Genital Herpes Simplex Virus Type 2 Infection. Journal of Infectious Diseases, 2007, 196, 505-509.	4.0	100

#	Article	IF	CITATIONS
271	Use of Longâ€Term Suppressive Acyclovir after Hematopoietic Stemâ€Cell Transplantation: Impact on Herpes Simplex Virus (HSV) Disease and Drugâ€Resistant HSV Disease. Journal of Infectious Diseases, 2007, 196, 266-270.	4.0	106
272	Topical Resiquimod 0.01% Gel Decreases Herpes Simplex Virus Type 2 Genital Shedding: A Randomized, Controlled Trial. Journal of Infectious Diseases, 2007, 195, 1324-1331.	4.0	98
273	Acute Hepatitis C in a Contemporary US Cohort: Modes of Acquisition and Factors Influencing Viral Clearance. Journal of Infectious Diseases, 2007, 196, 1474-1482.	4.0	165
274	One-year acyclovir prophylaxis for preventing varicella-zoster virus disease after hematopoietic cell transplantation: no evidence of rebound varicella-zoster virus disease after drug discontinuation. Blood, 2007, 110, 3071-3077.	1.4	186
275	Herpes Simplex Virus Type 2 and Risk of Intrapartum Human Immunodeficiency Virus Transmission. Obstetrics and Gynecology, 2007, 109, 403-409.	2.4	57
276	Prenatal Herpes Simplex Virus Serologic Screening Beliefs and Practices Among Obstetricians. Obstetrics and Gynecology, 2007, 110, 1364-1370.	2.4	9
277	Genital herpes. Lancet, The, 2007, 370, 2127-2137.	13.7	558
278	HSV: persistence in the population: epidemiology, transmission. , 2007, , 656-672.		50
279	Effect of maternal herpes simplex virus (HSV) serostatus and HSV type on risk of neonatal herpes. Acta Obstetricia Et Gynecologica Scandinavica, 2007, 86, 523-529.	2.8	39
280	Genital herpes: antiviral therapy for symptom relief and prevention of transmission. Expert Opinion on Pharmacotherapy, 2006, 7, 665-675.	1.8	11
281	Diagnostics for Herpes Simplex Virus. Molecular Diagnosis and Therapy, 2006, 10, 17-28.	3.8	92
282	Genital HSV-1 infections. Sexually Transmitted Infections, 2006, 82, 189-190.	1.9	49
283	Repeatâ€Region Polymorphisms in the Gene for the Dendritic Cell–Specific Intercellular Adhesion Moleculeâ€3–Grabbing Nonintegrin–Related Molecule: Effects on HIVâ€1 Susceptibility. Journal of Infectious Diseases, 2006, 193, 698-702.	4.0	47
284	Clinical correlates of index values in the focus HerpeSelect ELISA for antibodies to herpes simplex virus type 2 (HSV-2). Journal of Clinical Virology, 2006, 36, 141-145.	3.1	16
285	A randomized controlled trial of a replication defective (gH deletion) herpes simplex virus vaccine for the treatment of recurrent genital herpes among immunocompetent subjects. Vaccine, 2006, 24, 914-920.	3.8	72
286	Human Herpesvirus 8 Infection Among Adolescents in the REACH Cohort. JAMA Pediatrics, 2006, 160, 937-42.	3.0	15
287	Comparative Efficacy of Famciclovir and Valacyclovir for Suppression of Recurrent Genital Herpes and Viral Shedding. Sexually Transmitted Diseases, 2006, 33, 529-533.	1.7	70
288	Genital Herpes Complicating Pregnancy. Obstetrics and Gynecology, 2006, 107, 741.	2.4	0

#	Article	IF	CITATIONS
289	Isolation of Herpes Simplex Virus From the Genital Tract During Symptomatic Recurrence on the Buttocks. Obstetrics and Gynecology, 2006, 108, 947-952.	2.4	6
290	Targeted prenatal herpes simplex virus testing: Can we identify women at risk of transmission to the neonate?. American Journal of Obstetrics and Gynecology, 2006, 194, 408-414.	1.3	35
291	Maternal herpes simplex virus antibody avidity and risk of neonatal herpes. American Journal of Obstetrics and Gynecology, 2006, 195, 115-120.	1.3	22
292	Knowledge of Partners' Genital Herpes Protects against Herpes Simplex Virus Type 2 Acquisition. Journal of Infectious Diseases, 2006, 194, 42-52.	4.0	107
293	Oral Herpes Simplex Virus Type 2 Reactivation in HIVâ€Positive and â€Negative Men. Journal of Infectious Diseases, 2006, 194, 420-427.	4.0	45
294	Fulminant, Acyclovir-Resistant, Herpes Simplex Virus Type 2 Hepatitis in an Immunocompetent Woman. Journal of Clinical Microbiology, 2006, 44, 1584-1586.	3.9	50
295	Sequence-Based Methods for Identifying Epidemiologically Linked Herpes Simplex Virus Type 2 Strains. Journal of Clinical Microbiology, 2006, 44, 2541-2546.	3.9	16
296	HIV serodiscordant sex partners and the prevalence of human herpesvirus 8 infection among HIV negative men who have sex with men: baseline data from the EXPLORE Study. Sexually Transmitted Infections, 2006, 82, 229-235.	1.9	36
297	High Risk of Human Immunodeficiency Virus in Men Who Have Sex with Men with Herpes Simplex Virus Type 2 in the EXPLORE Study. American Journal of Epidemiology, 2006, 164, 733-741.	3.4	67
298	HIV/AIDS: Management of Herpes Simplex Virus Type 2 Infection in HIV Type 1–Infected Persons. Clinical Infectious Diseases, 2006, 43, 347-356.	5.8	140
299	Genital Herpes Complicating Pregnancy. Obstetrics and Gynecology, 2005, 106, 845-856.	2.4	167
300	Poor Correlation Between Genital Lesions and Detection of Herpes Simplex Virus in Women in Labor. Obstetrics and Gynecology, 2005, 106, 268-274.	2.4	23
301	The Relationship between Condom Use and Herpes Simplex Virus Acquisition. Annals of Internal Medicine, 2005, 143, 707.	3.9	138
302	Herpes Simplex Virus Type 2 (HSV-2) Western Blot Confirmatory Testing Among Men Testing Positive for HSV-2 Using the Focus Enzyme-Linked Immunosorbent Assay in a Sexually Transmitted Disease Clinic. Sexually Transmitted Diseases, 2005, 32, 771-777.	1.7	71
303	Risk factors for herpes simplex virus transmission to pregnant women: A couples study. American Journal of Obstetrics and Gynecology, 2005, 193, 1891-1899.	1.3	56
304	Differentiation of herpes simplex virus types 1 and 2 in clinical samples by a real-time taqman PCR assay. Journal of Medical Virology, 2005, 76, 350-355.	5.0	108
305	The psychosocial impact of serological herpes simplex type 2 testing in an urban HIV clinic. Sexually Transmitted Infections, 2005, 81, 309-315.	1.9	25
306	A Population-Based Study of Primary Human Herpesvirus 6 Infection. New England Journal of Medicine, 2005, 352, 768-776.	27.0	417

#	Article	IF	CITATIONS
307	Expression of Cutaneous Lymphocyte–Associated Antigen and Eâ€selectin Ligand by Circulating Human Memory CD4+T Lymphocytes Specific for Herpes Simplex Virus Type 2. Journal of Infectious Diseases, 2005, 191, 243-254.	4.0	33
308	Acyclovir Sensitivity of Sequential Herpes Simplex Virus Type 2 Isolates from the Genital Mucosa of Immunocompetent Women. Journal of Infectious Diseases, 2005, 192, 1102-1107.	4.0	32
309	Vitamin A Supplementation and Genital Shedding of Herpes Simplex Virus among HIVâ€1–Infected Women: A Randomized Clinical Trial. Journal of Infectious Diseases, 2004, 189, 1466-1471.	4.0	62
310	Frequent Reactivation of Herpes Simplex Virus among HIVâ€l–Infected Patients Treated with Highly Active Antiretroviral Therapy. Journal of Infectious Diseases, 2004, 190, 693-696.	4.0	105
311	Oral shedding of herpes simplex virus type 2. Sexually Transmitted Infections, 2004, 80, 272-276.	1.9	54
312	Valacyclovir and Acyclovir for Suppression of Shedding of Herpes Simplex Virus in the Genital Tract. Journal of Infectious Diseases, 2004, 190, 1374-1381.	4.0	150
313	Targeting Virological Core Groups: A New Paradigm for Controlling Herpes Simplex Virus Type 2 Epidemics. Journal of Infectious Diseases, 2004, 190, 1610-1617.	4.0	20
314	HIV Infection and Human Herpesvirus-8 Oral Shedding Among Men Who Have Sex with Men. Journal of Acquired Immune Deficiency Syndromes (1999), 2004, 35, 233-238.	2.1	62
315	Development and Use of a Type-Specific Antibody Avidity Test Based on Herpes Simplex Virus Type 2 Glycoprotein G. Sexually Transmitted Diseases, 2004, 31, 508-515.	1.7	22
316	Introduction: Is viral shedding a surrogate marker for transmission of genital herpes?. Antiviral Research, 2004, 63, S3-S9.	4.1	16
317	Lessons from HIV and hepatitis viruses. Antiviral Research, 2004, 63, S11-S18.	4.1	2
318	HSV shedding. Antiviral Research, 2004, 63, S19-S26.	4.1	80
319	HSV-2 transmission. Antiviral Research, 2004, 63, S27-S35.	4.1	42
320	Type-specific testing for herpes simplex virus. Expert Review of Molecular Diagnostics, 2004, 4, 443-453.	3.1	20
321	Once-Daily Valacyclovir to Reduce the Risk of Transmission of Genital Herpes. New England Journal of Medicine, 2004, 350, 11-20.	27.0	658
322	Invasive aspergillosis before allogeneic hematopoietic stem cell transplantation: 10-year experience at a single transplant center. Biology of Blood and Marrow Transplantation, 2004, 10, 494-503.	2.0	132
323	The Effects of Herpes Simplex Virus-2 on HIV-1 Acquisition and Transmission: A Review of Two Overlapping Epidemics. Journal of Acquired Immune Deficiency Syndromes (1999), 2004, 35, 435-445.	2.1	490
324	Remission of HHV-8 and HIV-associated multicentric Castleman disease with ganciclovir treatment. Blood, 2004, 103, 1632-1634.	1.4	191

#	Article	IF	CITATIONS
325	Genital herpes and human immunodeficiency virus: double trouble. Bulletin of the World Health Organization, 2004, 82, 447-53.	3.3	91
326	Herpes simplex virus type 2 transmission: risk factors and virus shedding. Herpes: the Journal of the IHMF, 2004, 11 Suppl 3, 130A-137A.	0.3	35
327	Synergistic interactions between herpes simplex virus type-2 and human immunodeficiency virus epidemics. Herpes: the Journal of the IHMF, 2004, 11, 70-6.	0.3	17
328	Immunodominance among herpes simplex virus-specific CD8 T cells expressing a tissue-specific homing receptor. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 12899-12904.	7.1	55
329	Polymerase Chain Reaction for Detection of Herpes Simplex Virus (HSV) DNA on Mucosal Surfaces: Comparison with HSV Isolation in Cell Culture. Journal of Infectious Diseases, 2003, 188, 1345-1351.	4.0	293
330	Transferred Herpes Simplex Virus Immunity after Stemâ€Cell Transplantation: Clinical Implications. Journal of Infectious Diseases, 2003, 187, 801-808.	4.0	43
331	Disseminated Sporotrichosis Associated with Treatment with Immunosuppressants and Tumor Necrosis Factor–α Antagonists. Clinical Infectious Diseases, 2003, 37, 838-840.	5.8	86
332	Psychosocial impact of serological diagnosis of herpes simplex virus type 2: a qualitative assessment. Sexually Transmitted Infections, 2003, 79, 280-285.	1.9	61
333	Valacyclovir for the Suppression of Recurrent Genital Herpes in Human Immunodeficiency Virus–Infected Subjects. Journal of Infectious Diseases, 2003, 188, 1009-1016.	4.0	88
334	Effect of Serologic Status and Cesarean Delivery on Transmission Rates of Herpes Simplex Virus From Mother to Infant. JAMA - Journal of the American Medical Association, 2003, 289, 203.	7.4	595
335	T Cell Immunity to Herpes Simplex Viruses in Seronegative Subjects: Silent Infection or Acquired Immunity?. Journal of Immunology, 2003, 170, 4380-4388.	0.8	57
336	How Does Herpes Simplex Virus Type 2 Influence Human Immunodeficiency Virus Infection and Pathogenesis?. Journal of Infectious Diseases, 2003, 187, 1509-1512.	4.0	53
337	Prevalence and Risk Factors for Infection With Herpes Simplex Virus Type-1 and -2 Among Lesbians. Sexually Transmitted Diseases, 2003, 30, 890-895.	1.7	59
338	Natural History of Genital Herpes Simplex Virus Type 1 Infection. Sexually Transmitted Diseases, 2003, 30, 174-177.	1.7	139
339	Time Course of Seroconversion by HerpeSelect ELISA After Acquisition of Genital Herpes Simplex Virus Type 1 (HSV-1) or HSV-2. Sexually Transmitted Diseases, 2003, 30, 310-314.	1.7	78
340	Correlates of Human Herpesvirus-8 Seropositivity Among U.S. Military Members Recently Infected With Human Immunodeficiency Virus. Sexually Transmitted Diseases, 2003, 30, 713-718.	1.7	14
341	Epidemiology and Outcome of Mould Infections in Hematopoietic Stem Cell Transplant Recipients. Clinical Infectious Diseases, 2002, 34, 909-917.	5.8	1,303
342	Risk of Human Immunodeficiency Virus Infection in Herpes Simplex Virus Type 2–Seropositive Persons: A Metaâ€analysis. Journal of Infectious Diseases, 2002, 185, 45-52.	4.0	669

#	Article	IF	CITATIONS
343	Correlates of Prevalent and Incident Kaposi's Sarcoma–Associated Herpesvirus Infection in Men Who Have Sex with Men. Journal of Infectious Diseases, 2002, 185, 990-993.	4.0	76
344	Twoâ€Đay Regimen of Acyclovir for Treatment of Recurrent Genital Herpes Simplex Virus Type 2 Infection. Clinical Infectious Diseases, 2002, 34, 944-948.	5.8	106
345	Serological Testing for Herpes Simplex Virus (HSV)–1 and HSVâ€2 Infection. Clinical Infectious Diseases, 2002, 35, S173-S182.	5.8	169
346	Quantitative Stability of DNA after Extended Storage of Clinical Specimens as Determined by Real-Time PCR. Journal of Clinical Microbiology, 2002, 40, 2609-2611.	3.9	134
347	Genital Shedding of Herpes Simplex Virus among Men. Journal of Infectious Diseases, 2002, 186, S34-S39.	4.0	78
348	Assessment of a Combined Testing Strategy for Detection of Antibodies to Human Herpesvirus 8 (HHV-8) in Persons with Kaposi's Sarcoma, Persons with Asymptomatic HHV-8 Infection, and Persons at Low Risk for HHV-8 Infection. Journal of Clinical Microbiology, 2002, 40, 3822-3825.	3.9	31
349	HHV-8 infection: a model for reactivation and transmission. Reviews in Medical Virology, 2002, 12, 47-63.	8.3	40
350	Expression of cutaneous lymphocyte-associated antigen by CD8+ T cells specific for a skin-tropic virus. Journal of Clinical Investigation, 2002, 110, 537-548.	8.2	103
351	Expression of cutaneous lymphocyte-associated antigen by CD8+ T cells specific for a skin-tropic virus. Journal of Clinical Investigation, 2002, 110, 537-548.	8.2	72
352	Condom use and the prevention of genital herpes acquisition. Herpes: the Journal of the IHMF, 2002, 9, 10-4.	0.3	8
353	Testing for genital herpes: how, who, and why. Current Clinical Topics in Infectious Diseases, 2002, 22, 166-80.	0.3	5
354	Demographic rather than behavioral risk factors predict herpes simplex virus type 2 infection in sexually active adolescents. Pediatric Infectious Disease Journal, 2001, 20, 422-426.	2.0	33
355	Corynebacterium jeikeium bacteremia in bone marrow transplant patients with Hickman catheters. Bone Marrow Transplantation, 2001, 27, 445-449.	2.4	52
356	Effect of Condoms on Reducing the Transmission of Herpes Simplex Virus Type 2 From Men to Women. JAMA - Journal of the American Medical Association, 2001, 285, 3100.	7.4	271
357	CD8 CTL from Genital Herpes Simplex Lesions: Recognition of Viral Tegument and Immediate Early Proteins and Lysis of Infected Cutaneous Cells. Journal of Immunology, 2001, 166, 4049-4058.	0.8	117
358	Herpes Simplex Virus Type 1 as a Cause of Genital Herpes: Impact on Surveillance and Prevention. Journal of Infectious Diseases, 2000, 181, 1454-1457.	4.0	233
359	Premarket Evaluation of the POCkit HSV-2 Type-Specific Serologic Test in Culture-Documented Cases of Genital Herpes Simplex Virus Type 2. Sexually Transmitted Diseases, 2000, 27, 266-269.	1.7	47
360	Mucosal Shedding of Human Herpesvirus 8 in Men. New England Journal of Medicine, 2000, 343, 1369-1377.	27.0	440

#	Article	IF	CITATIONS
361	Herpes Simplex Virus Type 2 Shedding in Human Immunodeficiency Virus—Negative Men Who Have Sex with Men: Frequency, Patterns, and Risk Factors. Clinical Infectious Diseases, 2000, 30, 261-267.	5.8	64
362	Herpes simplex virus: the importance of asymptomatic shedding. Journal of Antimicrobial Chemotherapy, 2000, 45, 1-8.	3.0	129
363	Reactivation of Genital Herpes Simplex Virus Type 2 Infection in Asymptomatic Seropositive Persons. New England Journal of Medicine, 2000, 342, 844-850.	27.0	533
364	Genital Herpes. , 2000, , 311-323.		0
365	Genital Herpes: Review of the Epidemic and Potential Use of Type-Specific Serology. Clinical Microbiology Reviews, 1999, 12, 1-8.	13.6	209
366	Development of a High-Throughput Quantitative Assay for Detecting Herpes Simplex Virus DNA in Clinical Samples. Journal of Clinical Microbiology, 1999, 37, 1941-1947.	3.9	226
367	An Interactive, Computer-Based Program to Educate Patients About Genital Herpes. Sexually Transmitted Diseases, 1999, 26, 364-368.	1.7	11
368	Detection of Herpes Simplex Virus DNA in Semen of Men With Genital HSV-2 Infection. Sexually Transmitted Diseases, 1999, 26, 1-3.	1.7	35
369	New Therapies and Prevention Strategies for Genital Herpes. Clinical Infectious Diseases, 1999, 28, S4-S13.	5.8	52
370	Association of Major Histocompatibility Complex Determinants with the Development of Symptomatic and Asymptomatic Genital Herpes Simplex Virus Type 2 Infections. Journal of Infectious Diseases, 1999, 179, 1077-1085.	4.0	52
371	New developments in the epidemiology, natural history and management of genital herpes. Antiviral Research, 1999, 42, 1-14.	4.1	90
372	HERPES SIMPLEX VIRUS–2 INFECTION. Infectious Disease Clinics of North America, 1998, 12, 47-61.	5.1	75
373	HERPES. Dermatologic Clinics, 1998, 16, 795-797.	1.7	9
374	Herpes Simplex Virus Shedding among Human Immunodeficiency Virus â€Negative Men Who Have Sex with Men: Site and Frequency of Shedding. Journal of Infectious Diseases, 1998, 178, 978-982.	4.0	35
375	Cytomegalovirus Gastropathy in a Child: Resolution After Ganciclovir Therapy. Clinical Infectious Diseases, 1998, 26, 199-200.	5.8	2
376	Evidence of Latency and Reactivation of Both Herpes Simplex Virus (HSV)â€1 and HSVâ€2 in the Genital Region. Journal of Infectious Diseases, 1998, 177, 1069-1072.	4.0	78
377	Immunotherapy of Recurrent Genital Herpes with Recombinant Herpes Simplex Virus Type 2 Glycoproteins D and B: Results of a Placebo ontrolled Vaccine Trial. Journal of Infectious Diseases, 1997, 176, 1129-1134.	4.0	171
378	Epidemiology of <i>Aspergillus</i> Infections in a Large Cohort of Patients Undergoing Bone Marrow Transplantation. Journal of Infectious Diseases, 1997, 175, 1459-1466.	4.0	717

#	Article	lF	CITATIONS
379	Genital Herpes in a Primary Care Clinic. Sexually Transmitted Diseases, 1997, 24, 149-155.	1.7	80
380	Frequent genital herpes simplex virus 2 shedding in immunocompetent women. Effect of acyclovir treatment Journal of Clinical Investigation, 1997, 99, 1092-1097.	8.2	345
381	Suppression of Subclinical Shedding of Herpes Simplex Virus Type 2 with Acyclovir. Annals of Internal Medicine, 1996, 124, 8.	3.9	238
382	A large-scale, placebo-controlled, dose-ranging trial of peroral valaciclovir for episodic treatment of recurrent herpes genitalis. Valaciclovir HSV Study Group. Archives of Internal Medicine, 1996, 156, 1729-1735.	3.8	35
383	Subclinical Shedding of HSV: Its Potential for Reduction by Antiviral Therapy. Advances in Experimental Medicine and Biology, 1996, 394, 11-16.	1.6	9
384	Measuring health-related quality of life in persons with genital herpes. Quality of Life Research, 1995, 4, 532-539.	3.1	22
385	Virologic Characteristics of Subclinical and Symptomatic Genital Herpes Infections. New England Journal of Medicine, 1995, 333, 770-775.	27.0	491
386	Clinical and epidemiologic features of infection with Mycobacterium genavense. Swiss HIV Cohort Study. Archives of Internal Medicine, 1995, 155, 400-404.	3.8	12
387	Zidovudine compared with didanosine in patients with advanced HIV type 1 infection and little or no previous experience with zidovudine. AIDS Clinical Trials Group. Archives of Internal Medicine, 1995, 155, 961-974.	3.8	34
388	Influence of HIV Infection on Manifestations and Natural History of Other Sexually Transmitted Diseases. , 1993, 14, 19-42.		0
389	Infection with a Fastidious Mycobacterium Resembling <i>Mycobacterium simiae</i> in Seven Patients with AIDS. Annals of Internal Medicine, 1992, 117, 586-589.	3.9	53